Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

En studie av TORL-5-700 ved tilbakefallende/refraktær non-Hodgkins lymfom

24. september 2026 oppdatert av: TORL Biotherapeutics, LLC

En fase 1/2, første-på-mennesker, åpen-etikett, multisenterstudie av TORL-5-700 som monoterapi og i kombinasjon for deltakere med tilbakevendende eller refraktær non-Hodgkin lymfom

A Phase 1/2 study to evaluate safety, tolerability, and anticancer activity of TORL-5-700 as a monotherapy and in combination in R/R NHL

Studieoversikt

Studietype

Intervensjonell

Registrering (Antatt)

155

Fase

  • Fase 2
  • Fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • California
      • Fullerton, California, Forente stater, 92835
        • Rekruttering
        • Providence Medical Foundation
      • Los Alamitos, California, Forente stater, 90720
        • Rekruttering
        • Cancer and Blood Specialty Clinic, Los Alamitos
      • Santa Monica, California, Forente stater, 90404
        • Rekruttering
        • UCLA
      • Stanford, California, Forente stater, 94305
        • Rekruttering
        • Stanford University
    • Florida
      • Miami, Florida, Forente stater, 33136
        • Rekruttering
        • University of California Miami, Sylvester Comprehensive Cancer Center
    • Iowa
      • Iowa City, Iowa, Forente stater, 52242
        • Rekruttering
        • University of Iowa Health Care
    • Kansas
      • Wichita, Kansas, Forente stater, 67214
        • Rekruttering
        • Cancer Center of Kansas, Wichita
    • Tennessee
      • Nashville, Tennessee, Forente stater, 37203
        • Rekruttering
        • Sarah Cannon Research Institute
    • Texas
      • Dallas, Texas, Forente stater, 75390
        • Rekruttering
        • University of Texas Southwestern Medical Center

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Confirmed B-NHL, including but not limited to de novo DLBCL; FL, Grades 1 to 3A; MCL; transformed lymphoma (tFL, RT) and FL Grade 3B; MZL and MALT.
  • Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2.
  • At least 1 measurable lesion per Lugano criteria.
  • Tumor tissue is available.
  • Adequate organ function

Exclusion Criteria:

  • T-cell lymphoma
  • CLL or SL
  • Burkitt lymphoma and high-grade B-cell lymphoma
  • CNS involvement
  • Peripheral neuropathy > Grade 2
  • Uncontrolled medical conditions
  • Viral infections

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Ikke-randomisert
  • Intervensjonsmodell: Sekvensiell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Part 1: Monotherapy Dose Escalation

TORL-5-700 Administered once every three weeks

Part 1: Monotherapy Dose Escalation - TORL-5-700 Administered once every three weeks

Eksperimentell: Part 2: Monotherapy Expansion

TORL-5-700 at MTD/RP2D Administered once every three weeks

Part 2: Monotherapy Expansion - TORL-5-700 at Maximum tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) Administered once every three weeks

Eksperimentell: Part 3: Combination Evaluation

TORL-5-700 at MTD/RP2D Administered once every three weeks in combination with another agent

Part 3: Combination Evaluation - TORL-5-700 at MTD/RP2D administered every three weeks in combination with another agent

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Evaluate the safety of TORL-5-700 as a monotherapy
Tidsramme: though study completion, an average of 2.5 years

Assessment of adverse events according to NCI-CTCAE Version 5.0

though study completion, an average of 2.5 years
Assess the antitumor activity of TORL-5-700 as monotherapy
Tidsramme: though study completion, an average of 2.5 years

Assess the antitumor activity of TORL-5-700 using Cheson (2014) disease grading criteria

though study completion, an average of 2.5 years
Evaluate the safety of TORL-5-700 in combination with other agents
Tidsramme: though study completion, an average of 2.5 years

Assessment of adverse events according to NCI-CTCAE Version 5.0

though study completion, an average of 2.5 years
Determine the Maximum Tolerated Dose (MTD)
Tidsramme: 21 days from the start of treatment

Determine the MTD by assessing Protocol defined Dose Limiting Toxicities (DLT)

21 days from the start of treatment
Determine the Recommended Phase 2 Dose (RP2D)
Tidsramme: 21 days from the start of treatment

Determine the RP2D by assessing Protocol defined Dose Limiting Toxicities

21 days from the start of treatment

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Maximum Serum Concentration of TORL-5-700 (Cmax)
Tidsramme: though end of study treatment, an average of 5 months

Pk assessment

though end of study treatment, an average of 5 months
Maximum Serum Concentration of TORL-5-700 (Cmax) in combination with other agents
Tidsramme: though end of study treatment, an average of 5 months

Pk assessment

though end of study treatment, an average of 5 months
Terminal Half-life (t1/2) of Serum TORL-5-700
Tidsramme: though end of study treatment, an average of 5 months

Pk assessment

though end of study treatment, an average of 5 months
Terminal Half-life (t1/2) of Serum TORL-5-700 in combination with other agents
Tidsramme: though end of study treatment, an average of 5 months

Pk assessment

though end of study treatment, an average of 5 months
Area under the Serum Concentration -Time curve for TORL-5-700 from the time of dosing to the last measurable concentration
Tidsramme: though end of study treatment, an average of 5 months

Pk assessment

though end of study treatment, an average of 5 months
Area under the Serum Concentration -Time curve for TORL-5-700 from the time of dosing to the last measurable concentration in combination with other agents
Tidsramme: though end of study treatment, an average of 5 months

Pk assessment

though end of study treatment, an average of 5 months
Clearance (CL) of TORL-5-700
Tidsramme: though end of study treatment, an average of 5 months

Pk assessment

though end of study treatment, an average of 5 months
Clearance (CL) of TORL-5-700 in combination with other agents
Tidsramme: though end of study treatment, an average of 5 months

Pk assessment

though end of study treatment, an average of 5 months
Volume of distribution of TORL-5-700
Tidsramme: though end of study treatment, an average of 5 months

PK assessment

though end of study treatment, an average of 5 months
Volume of distribution of TORL-5-700 in combination with other agents
Tidsramme: though end of study treatment, an average of 5 months

PK assessment

though end of study treatment, an average of 5 months
Immunogenicity of TORL-5-700
Tidsramme: though end of study treatment, an average of 5 months

Immunogenicity will be measured by incidence of treatment emergent ADAs

though end of study treatment, an average of 5 months
Immunogenicity of TORL-5-700 in combination with other agents
Tidsramme: though end of study treatment, an average of 5 months

Immunogenicity will be measured by incidence of treatment emergent ADAs

though end of study treatment, an average of 5 months
Assess the preliminary antitumor activity of TORL-5-700 in combination with other agents
Tidsramme: though study completion, an average of 2.5 years

Assess the antitumor activity of TORL-5-700 in combination with other agents using Cheson (2014) disease grading criteria

though study completion, an average of 2.5 years

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

31. mars 2026

Primær fullføring (Antatt)

31. mars 2029

Studiet fullført (Antatt)

30. september 2029

Datoer for studieregistrering

Først innsendt

10. februar 2026

Først innsendt som oppfylte QC-kriteriene

23. februar 2026

Først lagt ut (Faktiske)

27. februar 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

28. september 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

24. september 2026

Sist bekreftet

1. august 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere